Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

Weidmann, E.; Neumann, A.; Fauth, F.; Atmaca, A.; Al-Batran, S. E.; Pauligk, C.; Jäger, E.
August 2011
Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1839
Academic Journal
Background: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. However, there is very little information regarding the management of elderly patients.Patients and methods: We initiated a phase II study of first-line treatment with rituximab and bendamustine in elderly patients (≥80 years) with aggressive B-cell lymphomas who were not eligible for R-CHOP or who did not agree to aggressive treatment. The treatment decision on eligibility for R-CHOP was left to discretion of the physicians.Results: Fourteen patients with a median age of 85 years (range 80–95 years) were included. The age-adjusted international prognostic index was zero in five patients, one in three patients, and two in six patients. Thirteen patients were assessable for response. Seven patients (54%) had a complete response, two (15%) a partial response, and four (31%) progressive disease. The median overall survival was 7.7 months, and the median progression-free survival 7.7 months; however, six patients (43%) were alive without disease at 20–72 months from the start of treatment. Major toxicity was neutropenia (17% grade 3 and 6% grade 4). All other grade 3 and 4 hematotoxicities and non-hematological toxic effects ranged between 2% and 11%Conclusions: Because of its efficacy and low toxicity, bendamustine in combination with rituximab may be an alternative treatment for aggressive lymphomas in old patients not eligible for R-CHOP. These results, however, need to be confirmed in larger studies.


Related Articles

  • Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ketterer, N.; Coiffier, B.; Thieblemont, C.; Fermé, C.; Brière, J.; Casasnovas, O.; Bologna, S.; Christian, B.; Connerotte, T.; Récher, C.; Bordessoule, D.; Fruchart, C.; Delarue, R.; Bonnet, C.; Morschhauser, F.; Anglaret, B.; Soussain, C.; Fabiani, B.; Tilly, H.; Haioun, C. // Annals of Oncology;Apr2013, Vol. 24 Issue 4, p1032 

    Background The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was...

  • The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. Meyer, Paul N.; Kai Fu; Greiner, Timothy; Smith, Lynette; Delabie, Jan; Gascoyne, Randy; Ott, German; Rosenwald, Andreas; Braziel, Rita; Campo, Elias; Vose, Julie; Lenz, Georg; Staudt, Louis; Chan, Wing; Weisenburger, Dennis D. // American Journal of Clinical Pathology;Jan2011, Vol. 135 Issue 1, p54 

    The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and...

  • Primary cutaneous large B-cell lymphoma, leg type. Thomas, Vibha; Dobson, Robin; Mennel, Robert // Baylor University Medical Center Proceedings;Oct2011, Vol. 24 Issue 4, p350 

    Primary cutaneous large B-cell lymphoma, leg type, is a rare and aggressive neoplasm as defined by the recently updated World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. We present a case of a 74-year-old woman who...

  • Treatment Strategies for Diffuse Large B Cell Lymphoma. Thieblemont, Catherine; Gisselbrecht, Christian // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 3, p57 

    The article discusses treatments for diffuse large B cell lymphoma (DLBCL). Considered as the most usual form of adult non-Hodgkin lymphoma (NHL), first line treatment for the disease is the combination therapy rituximab with cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP)....

  • Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Yang, Deok-Hwan; Ahn, Jae-Sook; Byun, Byung; Min, Jung; Kweon, Sun-Seog; Chae, Yee; Sohn, Sang; Lee, Sang; Kim, Hae; Jung, Sung-Hoon; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Bom, Hee-Seung; Lee, Je-Jung // Annals of Hematology;Apr2013, Vol. 92 Issue 4, p471 

    The prognostic accuracy of interim F-fluoro-2-dexoy- d-glucose positron emission tomography/computerized tomography (PET/CT) using three different methods of response assessments during rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy was investigated in 186...

  • A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Niitsu, Nozomi; Tamaru, Jun-ichi; Yoshino, Tadashi; Nakamura, Naoya; Nakamura, Shigeo; Ohshima, Kohichi; Nakamine, Hirokazu; Okamoto, Masataka // Annals of Hematology;Feb2011, Vol. 90 Issue 2, p185 

    In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The...

  • The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Gregoric, Brigita; Zadnik, Vesna; Novakovic, Barbara Jezersek // Radiology & Oncology;2012, Vol. 46 Issue 2, p153 

    Background. Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial...

  • Primary renal lymphoma—a case report. Geetha, N.; Shahid, Abdul; Rajan, Varun; Jacob, Priya Mary // Ecancermedicalscience;2014, Vol. 8 Issue 447-473, p1 

    Primary renal lymphoma is a rare entity representing less than 1% of lesions in the kidney. We present the case of a 42-year-old male who was evaluated for pain and a mass in the abdomen. The computed tomogram of the abdomen showed a large lobulated homogeneously enhancing mass lesion of about...

  • The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn, Byeong; Kim, Sun-Mok; Yoon, Dok; Kim, Shin; Lee, Dae; Kim, Jin-Ho; Lee, Sang-Wook; Huh, Jooryung; Suh, Cheolwon // Annals of Hematology;Nov2012, Vol. 91 Issue 11, p1731 

    The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell lymphoma (DLBCL). However, a few trials comparing CHOP plus rituximab (R-CHOP) with CHOP have been...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics